Kunena :: Тема: Posted by Dinah Mcghee on 30.11.2016 13:35:48: tarceva not working lung cancer (1/2)

Навигация: Главная Форум Главный раздел Сообщество базовых площадокPosted by Dinah Mcghee on 30.11.2016 13:35:48: tarceva not working lung cancer

Добро пожаловать, Гость

Форум

Главный раздел

Сообщество базовых площадок

Posted by Dinah Mcghee on 30.11.2016 13:35:48: tarceva not working lung cancer

Страница:
1
2

ТЕМА: Posted by Dinah Mcghee on 30.11.2016 13:35:48: tarceva not working lung cancer

Posted by Dinah Mcghee on 30.11.2016 13:35:48: tarceva not working lung cancer 7 года 5 мес. назад #942

akipk

High Quality - Low Cost Anti-Cancer Drugs

*
This new approval of the cobas ® EGFR Mutation Test v2 is to aid physicians in selecting patients with metastatic NSCLC with specific EGFR treatment mutations (i.e. exon 19 deletions and exon 21 L858R substitution mutations) in plasma specimens, also called liquid biopsy specimens, to aid physicians in identifying patients who may be treated first with TARCEVA ® (erlotinib). This new specimen may benefit patients who may be too ill or unable to provide a tumor specimen.
Non posso dare indicazioni precise per via web. Posso però osservare che la scelta di Tarceva segue alcune osservazioni recenti per cui dopo Iressa e poi un'altra chemioterapia, Tarceva potrebbe funzionare ancora. Alcuni utilizzano un farmaco analogo definito inibitore irreversibile (Afatinib) che tuttavia è gravato con marcata frequenza da diarrea come effetto collaterale. Cordiali Saluti.
Nello studio su pazienti che non avevano risposto alla chemioterapia precedente, i pazienti che assumevano Tarceva sono sopravvissuti in media 6,7 mesi, contro i 4,7 mesi dei pazienti trattati con placebo.Tra i pazienti che assumevano Tarceva, la media di sopravvivenza era di 8,6 mesi per quelli
laptop31.ru/forum/zayavi-o-sebe/865-post...and-h2-blockers.html
Two methods for delivering maintenance therapy have been explored 5. continuation maintenance involves continuing the nonplatinum component of the first-line regimen, whereas switch maintenance requires introducing a drug with proven efficacy in the second-line setting immediately after the end of induction chemotherapy, thereby ensuring patients have the opportunity to receive an additional treatment. Continuation maintenance with gemcitabine 15 and, recently, pemetrexed 16 have both demonstrated significant prolongation of progression-free survival (PFS) with potential improvement in OS, 15 whereas both erlotinib 17 and pemetrexed 18 have demonstrated improvements in PFS and OS in the switch maintenance setting. The mechanism of OS benefit in these trials has been widely discussed. 5 ,19 It has been questioned whether an imbalance in second-line drug exposure between the control and experimental arms may have led to an overestimation of OS benefit in both pemetrexed and erlotinib trials or whether the OS benefit was entirely as a result of the maintenance strategy (ie, to an increase in treatment duration). The trial by Fidias et al, 20 assessed docetaxel as either switch maintenance or conventional second-line therapy and found that the survival benefit from the switch maintenance strategy was mainly owing to more patients receiving docetaxel in the maintenance arm. Another important issue is the selection of patients who will benefit most from a maintenance strategy, especially regarding continuation versus switch maintenance. Patients with stable disease after first-line chemotherapy seem to benefit more from switch maintenance, 21 whereas continuation maintenance may be more effective for responders.
Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib
Although there are wide range of cytotoxic drugs with different mechanismsof action, most of them could not distinguish between cancerous and normal cell types. Growth factor signaling pathways have major role in regulating key cellular functions including cellproliferation,differentiation, metastasis and survival. An important mediator of growth factor signaling pathways is the human epidermal receptors (HERs). 1 Tyrosine kinase receptors, which belong to (HER) family, are over expressed in various types of solid tumors, including non-small-cell lung cancer (NSCLC).These receptors are cell membrane bound proteins that consist of three regions: an extracellular ligand binding site; an intracellular domain with tyrosine kinase activity and regulatory functions; and a region that binds the receptor to the cell membrane. 2 -4 Phosphorylation of tyrosine residues on HERs is an important stage in signal transduction, leading to cell proliferation for major human carcinomas. Therefore, interruption of this growth signal is a potential target for anticancer treatment. 5 Erlotinib, a 4-anilinoquinazoline, is a potent inhibitor of tyrosine kinase. It reversibly and selectively binds to the adenosine triphosphate (ATP) binding site of the tyrosine kinase domain associated with HERs. Consequently phosphorylation of the tyrosine kinase is inhibited and thereby it can interfere with cell communication, signal transduction and ultimately cellular growth. 6 The common method for preparation of 4-anilinoquinazolines such as erlotinib involves the construction of suitable 4-chloroquinazoline intermediate and then reacting of this intermediate with suitable substituted aniline in acidic media. The 4-chloroquinazolines are key intermediates and their preparation involve a series of reaction and the use of highly flammable gas such as hydrogen at high pressure, and costly reagents such platinum oxide. 7 Erlotinib hydrochloride was synthesized in seven steps starting from 3, 4-dihydroxy benzoic acid. In this study, we were able to modify one of the key steps which involved the reduction of the 6-nitrobenzoic acid derivative to 6-aminobenzoic acid derivative. An inexpensive reagent such as ammonium formate was used as an in situ hydrogen donor in the presence of palladium/charcoal (Pd/C) instead of hydrogen gas at high pressure. This modified method eliminated the potential danger associated with the use of hydrogen gas in the presence of flammable catalysts. Furthermore catalyst could be recovered and used again.
Erlotinib Impurity 7
10. Erlotinib is given orally at a recommended dosage of 150 mg/day. The cost of a pack of 30 (150-mg) tablets is £1,631.53. The manufacturer of erlotinib has agreed a revised patient access scheme with the Department of Health in which a confidential discount from the list price is applied to original invoices.
Development and application of an HPLC method for erlotinib protein binding studies.
The CSF penetration of erlotinib and OSI-420 calculated using the compartmental model were 7.0% and 9.5%, respectively. Because the CSF concentration of the samples obtained before and 24 h after erlotinib administration on day 34 did not fit well into the curve drawn based on the compartmental model (Fig. 3 ), we considered several alternatives to better describe the distribution of these samples (data not shown), including a nonlinear model that took into account the possible influence of erlotinib concentration on the transport between the plasma and CSF compartments. Because these variations in the model did not improve the fit, we also used a noncompartmental approach to determine the CSF penetration of erlotinib and OSI-420. The CSF penetration of erlotinib and OSI-420 were 6.9% and 8.6%, respectively, based on the ratio of the respective CSF and plasma AUC 0-24 (Table 1 ). The erlotinib CSF concentrations 4 and 8 h after dosage on day 34 of therapy were 129 ng/mL (322.5 nmol/L) and 139 ng/mL (347.5 nmol/L), respectively (Fig. 3 ).
bassein-delfin.gchelny.ru/index.php?opti...&id=11644&Itemid=362
A Phase I-II Study of OSI-774 (Tarceva, Erlotinib) With Docetaxel/Carboplatin Followed by Maintenance Therapy With Tarceva as Treatment for Newly Diagnosed Stage III/IV Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Tube Cancer
In our study, gefitinib treatment showed different adverse events to erlotinib treatment. Compared to the side effects of erlotinib, patients treated with gefitinib had a significantly higher frequency of liver dysfunction. In the gefitinib group, the rate of liver dysfunction of all grades in our study was 45.3%, including 19.0% of grade 1, 10.5% of grade 2, 14.7% of grade 3, and 1.1% of grade 4. In the erlotinib group, the rate of liver dysfunction in our study was 21.3%, including 8.2% of grade 1, 8.2% of grade 2, 4.9% of grade 3, and 0% of grade 4. With respect to gefitinib therapy, Maemondo et al. reported a rate of 55% of all grades of increased levels of aminotransferases, and the rate of grade 3 or 4 was 21.5% in a Japanese cohort [ 2 ]. Mitsudomi et al. reported a rate of 70.1% of all grades and a rate of 16.1% of grade 3 or 4 [ 25 ]. With respect to erlotinib therapy, an Asian phase III study showed a rate of 37% for all grades of increased levels of ALT, and a rate of 4% of grade 3 or 4 [ 26 ]. Our results were similar to those found in previous gefitinib and erlotinib phase III clinical trials in Asian subjects.
Because the prognostic and predictive significance of KRAS mutations in patients with advanced NSCLC, researchers sought to prospectively evaluate the prognostic and predictive role of KRAS mutations in patients with NSCLC treated with second-line docetaxel or erlotinib.
alschool.kiev.ua/index.php/component/kun...-time-to-progression
A Phase I Dose-Escalation Study of Erlotinib in Combination With Cetuximab in Subjects With Advanced Cancer. Companion Study to Umbrella Protocol 2007-0638.
In 2005, Erlotinib was approved in combination with Gemcitabine (anticancer nucleoside analog used as chemotherapy) for treatment of advanced pancreatic cancer
The dose of erlotinib (Tarceva ® ) your healthcare provider recommends will vary, depending on a number of factors, such as:
aum.com.ru/forum/10--/6119-posted-by-ode...cancer-survival#6119
home > drug interactions checker > erlotinib oral and metronidazole oral interactions
Erlotinib :- Tarceva™ (OSI-774)
Carcinoma polmonare non a piccole cellule (Tarceva somministrato in monoterapia) . In uno studio randomizzato in doppio cieco (BR.21; Tarceva somministrato come terapia di seconda linea), le reazioni avverse al farmaco segnalate più comunemente sono state rash (75 %) e diarrea (54 %), nella maggior parte dei casi di intensità pari al grado 1/2 e gestibili senza alcun intervento. Rash e diarrea di grado 3/4 si sono verificati, rispettivamente, nel 9 % e nel 6 % dei pazienti trattati con Tarceva ed entrambi hanno comportato la sospensione dallo studio per l’1 % dei pazienti. Rash e diarrea hanno richiesto una riduzione del dosaggio rispettivamente nel 6 % e nell’1 % dei pazienti. Nello studio BR.21, il tempo mediano di comparsa del rash è stato di 8 giorni e quello di comparsa della diarrea di 12 giorni. In generale il rash si manifesta come un’eruzione da lieve a moderata di tipo eritematoso e papulo–pustoloso, che può insorgere o peggiorare nelle aree esposte al sole. Per i pazienti che si espongono al sole può essere consigliabile l’uso di indumenti protettivi e/o di filtri solari (ad es. a base di sostanze minerali). La Tabella 1 riassume, in base al grado NCI–CTC (Criteri Comuni di Tossicità dell’Istituto Nazionale del Cancro), le reazioni avverse che si sono verificate con maggiore frequenza (≥3 %) tra i pazienti trattati con Tarceva rispetto al gruppo placebo nello studio registrativo BR.21 e almeno nel 10 % dei pazienti del gruppo Tarceva. Per classificare gli effetti indesiderati in base alla frequenza vengono usati i seguenti termini: molto comune (≥1/10); comune (≥1/100, <1/10); non comune (≥1/1.000, <1/100); raro (≥1/10.000, <1/1.000); molto raro (<1/10.000), comprese segnalazioni isolate. All’interno di ogni gruppo di frequenza le reazioni avverse sono presentate in ordine decrescente di gravità. Tabella 1: Reazioni avverse molto comuni nello studio BR.21
I found the following information at medical-dictionary.thefreedictionary.com/erlotinib 1. Drug-herb. Coenzyme Q10: decreased chemotherapy efficacy So much for CoQ10
In a statement to ET, Roche said it welcomed the decision of the court, which has upheld the patent covering erlotinib hydrochloride (Tarceva) and found Cipla to have infringed it.
Contenido del prospecto : 1. Qué es Tarceva y para qué se utiliza 2. Antes de tomar Tarceva 3. Cómo tomar Tarceva 4. Posibles efectos adversos 5. Conservación de Tarceva 6. Información adicional
Concurrent inhibition of epidermal growth factor receptor (EGFR) and cyclooxygenase-2 (COX-2) is an active and well tolerated regimen in recurrent head and neck cancer (HNC). In the current phase 1 trial, the authors sought to determine the maximum tolerated dose (MTD) and efficacy of concurrent erlotinib and celecoxib as a radiosensitizing regimen.
petersburglife.ru/index.php?option=com_f...catid=5&id=6426#6426
Strength: ERLOTINIB 100mg, ERLOTINIB 150mg
Saben que costo tiene en mexico el Erlotinib (Tarceva) es un medicamento para el cancer de pulmon?
www.blago-svet.com.ua/index.php?option=c...id=5753&lang=en#5753
Phase Ib: Frequency and characteristics of Dose Limiting Toxicity (DLTs) to the INC280 and erlotinib combination [ Time Frame: First 28 days of dosing ] [ Designated as safety issue: No ]
Adjuvant erlotinib did not prolong DFS in patients with EGFR -expressing NSCLC or in the EGFR m-positive subgroup. Further evaluation of erlotinib is warranted in the EGFR m-positive subgroup.
In this study, we examined the potential roles of a panel of miRNAs in erlotinib resistance of NSCLC. We measured the expression profiles of several miRNAs in both human non-small lung epithelial adenocarcinoma cell line Type II (A549) cells and acquired erlotinib-resistant A549 (A549-ER) cells. We found that erlotinib-induced down-regulation of miR-17-5p in A549-ER cells could increase EZH1 expression. Consistently, tumor and plasma miR-17-5p levels were down-regulated in erlotinib-resistant NSCLC patients. Taken together, all the results suggest that miR-17-5p plays a vital role in the development of erlotinib resistance in NSCLC and plasma miR-17-5p might be a potential biomarker of erlotinib response in NSCLC patients.
Title Glioblastoma Multiforme: Molecular Basis of Resistance to Erlotinib Book Title Tumors of the Central Nervous System, Volume 1 Book Subtitle Gliomas: Glioblastoma (Part 1) Pages pp 259-267 Copyright 2011 DOI 10.1007/978-94-007-0344-5_27 Print ISBN 978-94-007-0343-8 Online ISBN 978-94-007-0344-5 Series Title Tumors of the Central Nervous System Series Volume 1 Publisher Springer Netherlands Copyright Holder Springer Science+Business Media B.V. Additional Links
Erlotinib hydrochloride or Erlotinib is widely used to treat non-small cell lung cancer (NSCLC), pancreatic cancer and numerous other types of cancer.
shashki.zp.ua/index.php?option=com_kunen...tmenu=148&Itemid=146
I was dx for lupus it turned out I had lung cancer because after my surgery all symptoms of lupus disappeared this happened when I was 57 I started with radiation and chemo decided to stop treatment ( 2nd opinion ) to have surgery instead. after surgery i asked dr to give me chemo to clean up any strays cells they told me that I didn't need it first mist ake. Following year it went to brain 3 tumors bleeding, wbr worked well I was put on tarceva I was givin 3-6 months to live that was almost 4 years ago so never give up stay positive anything can happen when
Su farmacéutico le puede dar más información acerca de erlotinib.